CytRx keeps an eye on the suspicious activities of cancers. The drug developer is researching and developing several drug candidates to treat conditions such as chronic and acute forms of leukemia, pancreatic cancer, stomach cancer, and soft-tissue sarcomas (malignant tumors). Its pipeline drugs include enhanced chemotherapy agents and proprietary cancer cell inhibiting drugs. The company has sold off all of its non-oncology assets to focus on its drugs in late stage clinical trials.